GSK-3-beta (total) ELISA Kit (DEIA3523)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

cell lysates
Species Reactivity
Intended Use
GSK-3-beta (total) ELISA Kit is a complete kit for the quantitative determination of pan or total GSK-3-beta in cell lysates.
Contents of Kit
1. GSK-3 Microtiter Plate
2. Total GSK-3 EIA Antibody
3. Assay Buffer
4. Total GSK-3 EIA Conjugate
5. Wash Buffer Concentrate
6. GSK-3 Standard
7. TMB Substrate
8. Stop Solution
9. RIPA Cell Lysis Buffer
10. Plate Sealer
All components of this kit, except the Conjugate and Standard, are stable at 4°C until the kit's expiration date. The Conjugate and Standard must be stored at -20°C. For more detailed information, please download the following document on our website.
74.4 pg/mL


Have you cited DEIA3523 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Protein kinase-coding genes as novel diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma


Authors: Atay, Sevcan

Aim: This study aims to identify the prognostic and diagnostic significance of protein kinase-coding genes in pancreatic ductal adenocarcinoma (PDAC), products of which constitute one of the main classes of drug targets in cancer treatment. Material and Methods: Whole-genome gene expression data from seven PDAC cohorts (GSE62452, GSE15471, GSE62165, GSE18670, GSE19280, GSE41368, GSE71989) were included in the integrative transcriptomic analysis (n tumor=252, ncontrol=131). The differentially expressed genes in PDAC compared to controls were identified using random- effects model and were further validated in TCGA (The Cancer Genome Atlas) combined GTEx (Genotype-Tissue Expression) cohort (n tumor=179, ncontrol=171). The prognostic significance of the identified genes was then evaluated by integrating survival and transcriptome data of over 530 (n=530-1302) patients using OSpaad. Results: The integrative transcriptomic analysis revealed a total of seven down-regulated and 33 up-regulated protein kinase-coding genes in PDAC (adjusted p-value <= 0,05, -2 <= z-value <= 2). The validation analysis using TCGA combined GTEx data confirmed 80% (n=32) of the identified differentially expressed genes in PDAC (p<0,01, and fold change >= 2). Amongst, the elevated mRNA expressions of 9 genes (PTK2, TAOK1, CSNK1A1, EIF2AK2, WNK1, CDK12, CDK6, GSK3B, and MAP4K4) were found to be significantly correlated with worse overall survival of patients with PDAC (Logrank p <= 0,05, HR>1). Overexpression of SYK and PRKACB were correlated with better overall survival (Logrank p <= 0,05, HR<1). Discussion: The results of this study suggest that mRNA expression of the identified eleven protein kinase-coding genes can be used as both prognostic and diagnostic biomarkers for further clinical validation.

The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways


Authors: Santio, Niina M.; Salmela, Maria; Arola, Heidi; Eerola, Sini K.; Heino, Jyrki; Rainio, Eeva-Marja; Koskinen, Paivi J.

The ability of cells to migrate and form metastases is one of the fatal hallmarks of cancer that can be conquered only with better understanding of the molecules and regulatory mechanisms involved. The oncogenic PIM kinases have been shown to support cancer cell survival and motility, but the PIM-regulated pathways stimulating cell migration and invasion are less well characterized than those affecting cell survival. Here we have identified the glycogen synthase kinase 3 beta (GSK3B) and the forkhead box P3 (FOXP3) transcription factor as direct PIM targets, whose tumour-suppressive effects in prostate cancer cells are inhibited by PIM-induced phosphorylation, resulting in increased cell migration. Targeting GSK3B is also essential for the observed PIM-enhanced expression of the prostaglandin-endoperoxide synthase 2 (PTGS2), which is an important regulator of both cell migration and adhesion. Accordingly, selective inhibition of PIM activity not only reduces cell migration, but also affects integrin-mediated cell adhesion. Taken together, these data provide novel mechanistic insights on how and why patients with metastatic prostate cancer may benefit from therapies targeting PIM kinases, and how such approaches may also be applicable to inflammatory conditions. (C) 2016 Elsevier Inc. All rights reserved.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket